Lexicon’s Zynquista (sotagliflozin) is an oral dual inhibitor of the sodium-dependent glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). Image Credit: MacroEcon / Shutterstock.
An image of antimicrobial susceptibility testing in a petri dish. Advances in rapid nanomotion-based susceptibility testing, and MALDI-TOF-MS are providing more options for drug resistance
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s
Reunion Neuroscience, a New Jersey biotech that spun out from the ill-fated ketamine clinic chain Field Trip Health two years ago, has announced a $103m Series A
A new report on the first human bird flu case tied to the outbreak in cows in the United States suggests that the Texas man
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning! A crowdsourced
MORRISTOWN, N.J., May 02, 2024 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced the
Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Mindful Health Solutions (MHS),